GlassScriptPhysician profile
Sanjeevani Jain
NPI 1902887235
$16,016.22
in general payments reported to CMS, 2019-2025
32 companies · $816 in 2025
The $816 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,128 · 2020: $3,289 · 2021: $2,764 · 2022: $2,461 · 2023: $2,904 · 2024: $1,655 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,066.85 | 2021-2025 | |
| Allergan, INC. | $2,480.32 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $2,093.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,448.43 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $1,333.23 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,195.48 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $629.90 | 2019-2025 | Trintellix |
| Alkermes, INC. | $542.28 | 2019-2025 | Lybalvi, Aristada |
| Neos Therapeutics, LP | $377.21 | 2019-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $377.08 | 2019-2024 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $301.34 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $275.51 | 2019-2022 | |
| Axsome Therapeutics, INC. | $243.94 | 2022-2025 | Auvelity |
| Almatica Pharma LLC | $211.04 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $196.22 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $186.38 | 2022-2023 | Qelbree |
| Novo Nordisk INC | $152.59 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $145.47 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Tris Pharma INC | $120.08 | 2021-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $84.39 | 2019-2021 | |
| Eisai INC. | $75.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $60.39 | 2019-2023 | Spravato |
| Corium, LLC | $59.35 | 2022-2024 | Azstarys |
| Vertical Pharmaceuticals, LLC | $55.73 | 2019 | |
| Harmony Biosciences LLC | $42.28 | 2020-2023 | Wakix |
| Shire North American Group INC | $41.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.59 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2024 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.96 | 2023 | |
| Adlon Therapeutics L.P. | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeevani Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.